| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-07-17 | Paion (Germany) | € 8 million | private placement | two undisclosed U.S. institutional investors | CNS diseases | Private placement |
| 2017-07-07 | Biophytis (France) | € 18,7 million | capital increase - private placement | Bracknor Investment Group (Dubai) | Ageing diseases - Muscle disorders - Ophtalmological diseases | Capital increase |
| 2017-07-06 | Evotec (Germany) | grant | Hamburgische Investitions- und Förderbank (IFB Hamburg) (Germany) | Cancer - Oncology | Grant | |
| 2017-07-06 | Zealand Pharma (Denmark) | capital increase | Capital increase | |||
| 2017-07-05 | Anaeropharma Science (Japan) | $13.2 million | financing round | Novartis (Switzerland) Shinsei Corporate Investment (Japan) Seventure Partners (France) Innovation Network Corporation of Japan (Japan) Mitsubishi UFJ Capital (Japan) | Cancer - Oncology - Cardiovascular diseases | Financing round |
| 2017-07-03 | Sensorion (France) | up to €25 million | financing round | Yorkville Advisors Global (USA) | Otorhinolaryngology | Financing round |
| 2017-06-29 | Melinta Therapeutics (USA - CT) | $ 90 million | loan | Oberland Capital (USA - NY) | Infectious diseases | Loan |
| 2017-06-27 | Daytwo (Israel) | $12 million | series A financing round | Seventure Partners (France), J&J (USA - NJ) historical investors | Series A financing round | |
| 2017-06-27 | LogicBio Therapeutics (USA - MA) | $ 50 million | series B financing round | Arix Bioscience (UK) OrbiMed (USA - NY) Edmond de Rothschild Investment Partners (France) Pontifax (Israel) SBI Japan-Israel Innovation Fundalso (Israel - Japan) | Rare diseases - Genetic diseases - Infectious diseases | Series B financing round |
| 2017-06-26 | Sangamo Therapeutics (USA - CA) | $83.4 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2017-06-26 | BerGenBio (Norway) | NOK 24 million ($2.85m) | grant | Innovasjon Norge (Norway) | Cancer - Oncology | Grant |
| 2017-06-23 | Gensight Biologics (France) | €22.5 million | capital increase | Rare diseases - Genetic diseases - Ophtalmological diseases | Capital increase | |
| 2017-06-21 | Clovis Oncology (USA - CO) | $300 million | private placement | Cancer - Oncology | Private placement | |
| 2017-06-20 | iOnctura (Switzerland) | financing round | Merck Ventures (Germany) | Cancer - Oncology | Financing round | |
| 2017-06-20 | Loxo Oncology (USA - CA) | $260.8 million | private placement | Cancer - Oncology | Private placement | |
| 2017-06-20 | Onxeo (France) | €15 Million | private placement | Cancer - Oncology - Rare diseases | Private placement | |
| 2017-06-14 | Medixci (UK - Switzerland) | $300 million | financing round | Novartis (Switzerland) Verily, an Alphabet company (USA - CA) European Investment Fund (EIF) (EU) institutional LPs | Financing round | |
| 2017-06-12 | Abivax (France) | €390,000 | loan | Bpifrance (France) Région Occitanie /Pyrénées-Méditerranée (France) | Infectious diseases | Loan |
| 2017-06-09 | Idorsia (Switzerland) | IPO | Johnson&Johnson (J&J) (USA - NJ) | Cardiovascular diseases - CNS diseases - Immune diseases - Rare diseases | IPO | |
| 2017-06-08 | VBL Therapeutics (Israel) | $2.5 Million | grant | Israel Innovation Authority (Israel) formerly known as the Office of the Chief Scientist (OCS) | Cancer - Oncology | Grant |
